Cullinan Oncology Announces Management Transition
Cullinan Oncology (Nasdaq: CGEM) announced that Jon Wigginton, M.D. will step down as Chief Medical Officer to assume the role of Chairman of the Scientific Advisory Board and Senior Advisor to the CEO. CEO Owen Hughes acknowledged Wigginton's significant contributions to the company's transition to a clinical-stage biotech and the establishment of its clinical infrastructure. Wigginton expressed his enthusiasm to continue working closely with Cullinan's team to advance their innovative cancer therapies.
- Jon Wigginton's transition to Chairman of the Scientific Advisory Board may provide strategic oversight for the company's clinical programs.
- Continued leadership by Wigginton could enhance Cullinan's pipeline advancement due to his extensive clinical development experience.
- Wigginton's departure from the day-to-day role may raise concerns about leadership continuity in clinical operations.
CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that Jon Wigginton, M.D. is stepping down from his day-to-day role as Chief Medical Officer, and will assume the role of Chairman of the company’s Scientific Advisory Board (SAB) and Senior Advisor to the CEO.
“I want to thank Jon for his many contributions to Cullinan, having helped the company transition to a public, clinical-stage biotech company, and establishing the clinical infrastructure necessary to run multiple global clinical trials,” stated Owen Hughes, Cullinan’s Chief Executive Officer. “More importantly, I’m delighted that we will continue to benefit from Jon’s experience and clinical development expertise as we progress a diversified pipeline of novel targeted and immuno-oncology agents into the clinic.”
“I am pleased to continue to work with Owen and my valued colleagues at Cullinan in our quest to help those living with cancer,” stated Dr. Wigginton. “I am looking forward to further assisting the outstanding team at Cullinan, and to providing strategic oversight of the depth and breadth of Cullinan’s innovative development programs.”
About Cullinan Oncology
Cullinan Oncology is a biopharmaceutical company that strives to deliver results for our various stakeholders through disciplined capital allocation, decisive action, prudent risk taking and creative business development. We seek to drive shareholder returns by focusing on the patient. The Company’s strategy is to build a diversified pipeline of targeted and immuno-oncology therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes. Learn more about Cullinan at www.cullinanoncology.com.
Contacts:
Investor Relations
investors@cullinanoncology.com
Jeffrey Trigilio
+1 617.410.4650
jtrigilio@cullinanoncology.com
FAQ
Who is replacing Jon Wigginton at Cullinan Oncology?
What impact does Jon Wigginton's role change have on Cullinan's clinical programs?
What is Cullinan Oncology's focus as a biopharmaceutical company?
When was the press release about Jon Wigginton's role change published?
